STRATEC Biomedical AG / Key word(s): Results Forecast/Change in Forecast 15.03.2016 23:48 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- STRATEC adjusts financial forecast Birkenfeld, March 15, 2016 STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX), publishes today an adjustment in its mid-term financial forecast. According to forecasts and expectations currently communicated by customers and given the business performance in the first two months of the 2016 financial year, the Board of Management of STRATEC Biomedical AG has reviewed and adjusted the Group's medium-term sales expectations. The company now expects to achieve average annual sales growth (CAGR) of around 6% in the period from 2014 to 2017. For the 2016 financial year, the Group expects its sales to grow to between EUR 150 million and EUR 154 million. The EBIT margin should be maintained at around the level attained in the 2015 financial year. --------------------------------------------------------------------------- Information and Explanation of the Issuer to this News: The previous mid-term forecast provided for average annual sales growth of eight to twelve percent through to 2017 based on the figures for the 2013 financial year (EUR 128.0 million) and for this to be accompanied by increasing profitability. Based on preliminary, unaudited figures, STRATEC Biomedical AG generated sales of EUR 146.9 million (previous year: EUR 144.9 million) with an EBIT margin of 18.3% (previous year: 16.6%) in the 2015 financial year. About STRATEC STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange. Further information can be obtained from: STRATEC Biomedical AG André Loy, Corporate Communications Gewerbestr. 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 [email protected] www.stratec.com 15.03.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: [email protected] Internet: www.stratec.com ISIN: DE000STRA555 WKN: STRA55 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------